J.H. Whitney Equity Partners V Sells 2,250,000 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder J.H. Whitney Equity Partners V sold 2,250,000 shares of Aveanna Healthcare stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the transaction, the insider owned 12,315,892 shares of the company’s stock, valued at approximately $141,632,758. The trade was a 15.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

J.H. Whitney Equity Partners V also recently made the following trade(s):

• On Thursday, August 20th, J.H. Whitney Equity Partners V sold 12,496,077 shares of Aveanna Healthcare stock. The shares were sold at an average price of $11.50, for a total transaction of $143,704,885.50.
• On Tuesday, June 30th, J.H. Whitney Equity Partners V sold 2,419,035 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.01, for a total transaction of $19,376,470.35.
• On Wednesday, June 24th, J.H. Whitney Equity Partners V sold 919,389 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.00, for a total transaction of $7,355,112.00.
• On Wednesday, June 3rd, J.H. Whitney Equity Partners V sold 5,842,240 shares of Aveanna Healthcare stock. The stock was sold at an average price of $6.24, for a total value of $36,455,577.60.

Aveanna Healthcare Price Performance

AVAH stock opened at $13.59 on Wednesday. Aveanna Healthcare Holdings Inc. has a 1 year low of $5.93 and a 1 year high of $13.98. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16. The stock’s 50 day moving average price is $9.83 and its 200 day moving average price is $7.99. The firm has a market cap of $2.97 billion, a P/E ratio of 11.05, a PEG ratio of 0.96 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.05. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%.The company had revenue of $670.48 million during the quarter, compared to the consensus estimate of $638.61 million. On average, sell-side analysts expect that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Raymond James Financial lifted their price objective on Aveanna Healthcare from $13.00 to $15.00 and gave the stock a “strong-buy” rating in a research report on Friday, August 14th. Truist Financial upped their target price on shares of Aveanna Healthcare from $11.00 to $15.00 and gave the company a “hold” rating in a report on Monday. BMO Capital Markets raised their price target on shares of Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd. Finally, Barclays boosted their price objective on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Aveanna Healthcare currently has an average rating of “Moderate Buy” and an average target price of $12.89.

Hedge Funds Weigh In On Aveanna Healthcare

Several institutional investors have recently added to or reduced their stakes in AVAH. AQR Capital Management LLC lifted its position in Aveanna Healthcare by 21.2% during the first quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock worth $142,000 after buying an additional 4,602 shares during the period. Goldman Sachs Group Inc. grew its holdings in Aveanna Healthcare by 8.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock valued at $1,842,000 after buying an additional 25,974 shares during the period. Jane Street Group LLC grew its holdings in Aveanna Healthcare by 522.0% in the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after buying an additional 63,010 shares during the period. Creative Planning increased its stake in shares of Aveanna Healthcare by 15.1% during the 2nd quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after acquiring an additional 6,171 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Aveanna Healthcare by 65.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after acquiring an additional 62,348 shares during the last quarter. 87.96% of the stock is currently owned by institutional investors and hedge funds.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $16 from $10 and upgraded AVAH to “outperform.” The upgrade reinforces the bullish outlook following the stock’s recent rally. Benzinga analyst coverage
• Positive Sentiment: Truist Financial increased its price target to $15 from $11, although it maintained a “hold” rating. Other analysts have also raised targets after Aveanna exceeded quarterly earnings and revenue expectations. Benzinga analyst coverage
• Positive Sentiment: Aveanna reported quarterly EPS of $0.22 versus the $0.17 consensus estimate and revenue of $670.48 million versus expectations of $638.61 million. The earnings beat supports the improved analyst outlook and investor interest in the shares.
• Neutral Sentiment: Management will participate in the Jefferies Healthcare Services and Technology Conference on September 15. The presentation and one-on-one investor meetings could provide additional business updates, but the event is not an immediate financial catalyst. Aveanna conference announcement
• Negative Sentiment: Major shareholders, including Bain Capital- and J.H. Whitney-affiliated holders, disclosed substantial sales in a roughly $176 million offering. Additional sales by CEO Jeff Shaner, director Rodney Windley, and insider Edwin Reisz at $11.50 per share could weigh on sentiment and increase concerns about selling pressure, even though these holders retained sizable positions. Home Health Care News offering report

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.